Arrowhead Pharmaceuticals
ARWR
#4071
Rank
S$3.05 B
Marketcap
$24.61
Share price
-2.30%
Change (1 day)
-36.35%
Change (1 year)

P/E ratio for Arrowhead Pharmaceuticals (ARWR)

P/E ratio as of November 2024 (TTM): -11.0

According to Arrowhead Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.9647. At the end of 2022 the company had a P/E ratio of -27.8.

P/E ratio history for Arrowhead Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-27.8-26.25%
2021-37.7-50.41%
2020-76.0-165.87%
2019115-425%
2018-35.5362.86%
2017-7.67483.66%
2016-1.31-67.75%
2015-4.07-23.84%
2014-5.35-33.88%
2013-8.09640.8%
2012-1.09-87.23%
2011-8.55-14.01%
2010-9.94406.6%
2009-1.9657.89%
2008-1.24-72.04%
2007-4.45-40.1%
2006-7.42-41.89%
2005-12.8-11.1%
2004-14.4626.42%
2003-1.981610.19%
2002-0.1157-61.49%
2001-0.3004

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-60.6 452.93%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
74.7-780.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-6.32-42.33%๐Ÿ‡บ๐Ÿ‡ธ USA
11.0-200.68%๐Ÿ‡บ๐Ÿ‡ธ USA
-4.13-62.34%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.